Features of gastrointestinal tract lesions in COVID-19 (review of current literature and own observations)
Abstract
The author's task in writing the article was to systematize the current literature on the nature of involvement of the gastrointestinal tract in the pathological process in COVID-19, to draw the attention of the medical audience to the features of the supervision of gastroenterological patients during the pandemic.
About the Author
A. S. Sarsenbayeva
South-Urals State Medical University
Russian Federation
Russian Federation
Chelyabinsk
References
1. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, № 11. P. 1061–1069.
2. Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time // Lancet Infect. Dis. 2020. Vol. 20, № 5. P. 533–534.
3. Guan W. J., Ni Z.-Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382, № 18. P. 1708–1720.
4. Jin X., Lian J.-S., Hu J.-H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms // Gut. 2020. Vol. 69, № 6. P. 1002–1009.
5. Pan L., Mu M., Yang P. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study // Am. J. Gastroenterol. 2020. Vol. 115, № 5. P. 766–773.
6. Zhou P., Yang X.-L., Wang X.-G. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin // BioRxiv: The preprint server for biology. 23.01.2020. URL: https://www.biorxiv.org/content/10.1101/2020.01.22.914952v1. doi: https://doi.org/10.1101/2020.01.22.914952.
7. Zhang H., Kang Z., Gong H. et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes // BioRxiv: The preprint server for biology. 31.01.2020. URL: https://www.biorxiv.org/content/10.1101/2020.01.30.927806v1. DOI: 10.1101/2020.01.30.927806.
8. Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS-CoV-2 // Gastroenterology. 2020. Vol. 158, № 6. P. 1831–1833.e3.
9. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor // Cell. 2020. Vol. 181, № 2. P. 271–280.e8. URL: http://www.ncbi.nlm.nih.gov/pubmed/32142651.
10. Hung I. F. N., Cheng V. C. C., Wu A. K. L. et al. Viral loads in clinical specimens and SARS manifestations // Emerg. Infect. Dis. 2004. Vol. 10, № 9. P. 1550–1557.
11. Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus // Sci. Adv. 2017. Vol. 3, № 11. P. eaao4966.
12. Holshue M. L., DeBolt C., Lindquist S. et al. First case of 2019 novel coronavirus in the United States // N. Engl. J. Med. 2020. Vol. 382, № 10. P. 929–936.
13. Tisoncik J. R., Korth M. J., Simmons C. P. et al. Into the eye of the cytokine storm // Microbiol. Mol. Biol. Rev. 2012. Vol. 76, № 1. P. 16–32.
14. Perrone F., Piccirillo M. C. Tocilizumab in COVID-19 pneumonia (TOCIVID-19): Full Text View // ClinicalTrials.gov. 12.04.2020. URL: https://clinicaltrials.gov/ct2/show/NCT04317092.
15. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19: Full Text View // ClinicalTrials.gov. 12.04.2020. URL: https://clinicaltrials.gov/ct2/show/NCT04315298.
16. Monteleone G., Ardizzone S. Are patients with inflammatory bowel disease at increased risk for COVID-19 infection? // J. Crohns Colitis. 2020. Vol. 14, № 9. P. 1334–1336.
17. Rubin D., Feuerstein J. D., Wang A. Y. et al. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary // Gastroenterology. 2020. Vol. 159, № 1. P. 350–357.
18. Tian Y., Rong L., Nian W. et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission // Aliment. Pharmacol. Ther. 2020. Vol. 51, № 9. P. 843–851.
19. Gutin L. S., Lam A. Y., Velayos F. S. et al. Going viral: management of IBD in the era of the COVID-19 pandemic // Dig. Dis. Sci. 2020. Vol. 65, № 6. P. 1571–1575.
20. Zhang Y., Geng X., Tan Y. et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system // Biomed. Pharmacother. 2020. Vol. 127. P. 110195.
21. Sabino-Silva R., Jardim A. C. G., Siqueira W. L. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis // Clin. Oral Investig. 2020. Vol. 24, № 4. P. 1619–1621.
22. Repici A., Maselli R., Colombo M. et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know // Gastrointest. Endosc. 2020. Vol. 92, № 1. P. 192–197.
23. Гриневич В. Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19 // Экспериментальная и клиническая гастроэнтерология. 2020. Т. 174, № 4. С. 3–18.
24. Guarner F. et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. February 2017.
25. Moon A. M., Webb G. J., Aloman C. et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry // J. Hepatol. 2020. Vol. 73, № 3. P. 705–708.
26. Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission // Gastroenterology. 2020. Vol. 158, № 6. P. 1518–1519.
27. Lan L., Xu D., Ye G. et al. Positive RT-PCR test results in patients recovered from COVID-19 // JAMA. 2020. Vol. 323, № 15. P. 1502–1503.
Review
For citations:
Sarsenbayeva A.S. Features of gastrointestinal tract lesions in COVID-19 (review of current literature and own observations). Title in english. 2020;15(4):14-18. (In Russ.)
Views:
83
Email this article 